10:29 AM EDT, 06/13/2024 (MT Newswires) -- JPMorgan Chase's ( JPM ) J.P. Morgan Life Sciences Private Capital said Thursday its first biotechnology venture capital fund closed above its $500 million target.

The 270 Life Sciences Private Capital Fund I investment vehicle invests in private biotechnology companies and its portfolio investments span cardiometabolic disease, oncology, immunology and genetic medicines, the company said.

Price: 192.80, Change: +1.27, Percent Change: +0.66